[ad_1]
The Ministry of Health published the guide “Rules of application of the Covid-19 mRNA vaccine”.
According to the guidelines in the guide, the instructions for vaccination are as follows:
- It is preferable to leave a period of two weeks (before and after) with other vaccines. In either case, it is not necessary to repeat both vaccines if the mRNA vaccine was administered before this interval.
- It can be administered with vaccines containing rabies, tetanus toxoid, and post-exposure vaccines, such as measles and hepatitis A / B vaccines, regardless of time intervals.
- The tuberculin skin test should be performed on the same day as the vaccine or postponed for at least four weeks after the vaccine is given.
- After the administration of the vaccine, the person must be informed about possible allergic reactions and must not leave the health center for 15 minutes.
- People with a history of allergies should not leave the health center for 30 minutes.
- In the later period, you should be instructed to apply to the nearest health institution in case any side effects develop.
- The data matrix must be read before vaccination. Information about the person to whom the vaccine is administered will be recorded in the “VACCINE” mobile app.
- Early and late adverse effects that may occur after administration of the pandemic COVID-19 vaccine will be reported through the Public Health Management System (HSYS), the Family Medicine Information System (AHBS), or the Management System. Hospital Information Office (HBYS).
- Until a second instruction, it will not be administered to active COVID-19 patients, those who have passed COVID-19 within 180 days (confirmed by PCR test) and have been in contact with a confirmed case of COVID-19 within 10 days prior to the administration of vaccines.
- Both doses of the vaccine must be administered with the same pandemic vaccine.
- During pregnancy There are no data on the administration of the mRNA vaccine (BNT162b2). It can be applied to pregnant women who are at high risk of severe transmission of COVID-19 if they so desire. It is preferred that it not be applied in the first trimester.
- Breast-feeding There are no data on the administration of the mRNA vaccine (BNT162b2) during the period. It can be applied to breastfeeding women who are at high risk for severe COVID-19, if they so desire.
- The vaccination decision is made based on the evaluation that the follow-up doctor must carry out for those who have a diagnosis of neurological diseases such as uncontrolled epilepsy and Guillain-Barré Syndrome, transverse myelitis, which can be aggravated by infection and the vaccine.
- Immunosuppressed individuals should receive the vaccine based on the follow-up physician’s evaluation to determine the time interval in which the response to the vaccine may be best.
- Intramuscular injection can cause bleeding in patients with thrombocytopenia and bleeding disorders.
- In the presence of anaphylaxis against any substance contained in the vaccine, the vaccine is not administered.
- After the first dose of vaccine. The second dose is not administered in the presence of a history of anaphylaxis.
- Vaccination should be postponed during acute attacks of chronic diseases in people with a fever of 38ºC or higher, in acute diseases that have not yet been diagnosed.
[ad_2]
